Medicus Pharma (MDCX) Competitors $4.00 +0.15 (+3.90%) As of 04/17/2025 03:49 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock MDCX vs. YMAB, NVCT, PLX, ENGN, TERN, SLDB, FHTX, AMRN, DSGN, and OCGNShould you be buying Medicus Pharma stock or one of its competitors? The main competitors of Medicus Pharma include Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Protalix BioTherapeutics (PLX), enGene (ENGN), Terns Pharmaceuticals (TERN), Solid Biosciences (SLDB), Foghorn Therapeutics (FHTX), Amarin (AMRN), Design Therapeutics (DSGN), and Ocugen (OCGN). These companies are all part of the "pharmaceutical products" industry. Medicus Pharma vs. Y-mAbs Therapeutics Nuvectis Pharma Protalix BioTherapeutics enGene Terns Pharmaceuticals Solid Biosciences Foghorn Therapeutics Amarin Design Therapeutics Ocugen Medicus Pharma (NASDAQ:MDCX) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, risk, earnings, community ranking, media sentiment, institutional ownership, profitability and dividends. Which has better earnings and valuation, MDCX or YMAB? Medicus Pharma has higher earnings, but lower revenue than Y-mAbs Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMedicus PharmaN/AN/AN/AN/AN/AY-mAbs Therapeutics$87.69M2.42-$21.43M-$0.67-7.00 Is MDCX or YMAB more profitable? Medicus Pharma has a net margin of 0.00% compared to Y-mAbs Therapeutics' net margin of -28.22%. Medicus Pharma's return on equity of 0.00% beat Y-mAbs Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Medicus PharmaN/A N/A N/A Y-mAbs Therapeutics -28.22%-24.61%-18.49% Do analysts recommend MDCX or YMAB? Medicus Pharma currently has a consensus target price of $12.00, indicating a potential upside of 200.00%. Y-mAbs Therapeutics has a consensus target price of $18.30, indicating a potential upside of 290.19%. Given Y-mAbs Therapeutics' higher possible upside, analysts clearly believe Y-mAbs Therapeutics is more favorable than Medicus Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Medicus Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.50Y-mAbs Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 2.91 Does the media refer more to MDCX or YMAB? In the previous week, Medicus Pharma and Medicus Pharma both had 4 articles in the media. Y-mAbs Therapeutics' average media sentiment score of 0.87 beat Medicus Pharma's score of 0.75 indicating that Y-mAbs Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Medicus Pharma 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Y-mAbs Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders have more ownership in MDCX or YMAB? 70.8% of Y-mAbs Therapeutics shares are owned by institutional investors. 22.5% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in MDCX or YMAB? Y-mAbs Therapeutics received 134 more outperform votes than Medicus Pharma when rated by MarketBeat users. However, 100.00% of users gave Medicus Pharma an outperform vote while only 63.30% of users gave Y-mAbs Therapeutics an outperform vote. CompanyUnderperformOutperformMedicus PharmaOutperform Votes4100.00% Underperform VotesNo VotesY-mAbs TherapeuticsOutperform Votes13863.30% Underperform Votes8036.70% SummaryY-mAbs Therapeutics beats Medicus Pharma on 7 of the 12 factors compared between the two stocks. Get Medicus Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for MDCX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDCX vs. The Competition Export to ExcelMetricMedicus PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.66M$6.46B$5.31B$7.35BDividend YieldN/A3.21%5.45%4.34%P/E RatioN/A6.9521.9417.82Price / SalesN/A231.01380.6697.73Price / CashN/A65.6738.2534.64Price / BookN/A5.936.453.98Net IncomeN/A$143.22M$3.22B$247.81M7 Day Performance10.80%1.11%0.74%0.28%1 Month Performance20.48%-13.21%-9.66%-7.60%1 Year PerformanceN/A-8.51%11.81%1.49% Medicus Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDCXMedicus PharmaN/A$4.00+3.9%$12.00+200.0%N/A$53.66MN/A0.00N/AGap UpYMABY-mAbs Therapeutics3.6401 of 5 stars$4.54-15.1%$18.30+303.1%-69.0%$205.29M$87.69M-8.41150Short Interest ↓News CoverageNVCTNuvectis Pharma2.0713 of 5 stars$8.70-8.7%$15.67+80.1%+29.9%$203.51MN/A-7.508PLXProtalix BioTherapeutics1.9959 of 5 stars$2.60-0.8%$15.00+476.9%+127.0%$202.89M$53.40M-20.00200ENGNenGene3.0055 of 5 stars$3.96-1.0%$24.13+509.2%-73.1%$201.87MN/A-6.8331Analyst RevisionNews CoverageTERNTerns Pharmaceuticals4.147 of 5 stars$2.24-6.7%$18.38+720.3%-47.3%$195.55MN/A-1.9040News CoverageGap DownSLDBSolid Biosciences3.4346 of 5 stars$2.52-6.7%$15.67+521.7%-70.7%$195.28M$8.09M-0.83100Positive NewsFHTXFoghorn Therapeutics2.058 of 5 stars$3.47-2.8%$13.17+279.4%-28.3%$192.97M$22.60M-1.81120AMRNAmarin0.2464 of 5 stars$9.36-4.6%N/A-47.0%$192.20M$228.61M-104.00360Gap DownHigh Trading VolumeDSGNDesign Therapeutics1.2697 of 5 stars$3.38+1.8%$8.00+136.7%-5.4%$191.86MN/A-3.9840Positive NewsOCGNOcugen1.2357 of 5 stars$0.65-6.5%$6.33+869.6%-48.5%$190.74M$4.06M-3.6380Positive News Related Companies and Tools Related Companies Y-mAbs Therapeutics Alternatives Nuvectis Pharma Alternatives Protalix BioTherapeutics Alternatives enGene Alternatives Terns Pharmaceuticals Alternatives Solid Biosciences Alternatives Foghorn Therapeutics Alternatives Amarin Alternatives Design Therapeutics Alternatives Ocugen Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDCX) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medicus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medicus Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MDCX Stock Free MDCX Stock Alerts